Biogenesis of the 20S proteasome is tightly regulated. The N-terminal propeptides protecting the active-site threonines are autocatalytically released only on completion of assembly. However, the trigger for the self-activation and the reason for the strict conservation of threonine as the active site nucleophile remain enigmatic. Here we use mutagenesis, X-ray crystallography and biochemical assays to suggest that Lys33 initiates nucleophilic attack of the propeptide by deprotonating the Thr1 hydroxyl group and that both residues together with Asp17 are part of a catalytic triad. Substitution of Thr1 by Cys disrupts the interaction with Lys33 and inactivates the proteasome. Although a Thr1Ser mutant is active, it is less efficient compared with wild type because of the unfavourable orientation of Ser1 towards incoming substrates. This work provides insights into the basic mechanism of proteolysis and propeptide autolysis, as well as the evolutionary pressures that drove the proteasome to become a threonine protease.
The 20S proteasome core particle (CP) is the key non-lysosomal protease of eukaryotic cells. Its seven different α and seven different β subunits assemble into four heptameric rings that are stacked on each other to form a hollow cylinder. While the inactive α subunits build the two outer rings, the \( \beta \) subunits form the inner rings. Only three out of the seven different \( \beta \) subunits, namely \( \beta_1, \beta_2 \) and \( \beta_5 \), bear N-terminal proteolytic active centres, and before CP maturation these are protected by propeptides1–3. In the last stage of CP biogenesis, the prosegments are autocatalytically removed through nucleophilic attack by the active site residue Thr1 on the preceding peptide bond involving Gly(-1)4,5. Release of the prosegments creates a functionally active CP that cleaves proteins into short peptides.

Although the chemical nature of the substrate-binding channel and hence substrate preferences are unique to each of the distinct active \( \beta \) subunits6–8, all active sites employ an identical reaction mechanism to hydrolyse peptide bonds2. Nucleophilic attack of Thr1O\(_\gamma\) on the carbonyl carbon atom of the scissile peptide bond creates a first cleavage product and a covalent acyl-enzyme intermediate. Hydrolysis of this complex by the addition of a nucleophilic water molecule regenerates the enzyme and releases the free N-terminal amine group of Thr1 was proposed to create a first cleavage product and a covalent acyl-enzyme intermediate. Hydrolysis of this complex by the addition of a nucleophilic water molecule regenerates the enzyme and releases the free N-terminal amine group of Thr1 was proposed to create a first cleavage product and a covalent acyl-enzyme intermediate. Hydrolysis of this complex by the addition of a nucleophilic water molecule regenerates the enzyme and releases the free N-terminal amine group of Thr1.

Results

Inactivation of proteasome subunits by T1A mutations. Proteasome-mediated degradation of cell-cycle regulators and potentially toxic misfolded proteins is required for the viability of eukaryotic cells8. Inactivation of the active site Thr1 by mutation to Ala has been used to study substrate specificity and the hierarchy of the proteasome active sites1,4,12–15. Yeast strains carrying the single mutations \( \beta_1\)-T1A or \( \beta_2\)-T1A, or both, are viable, even though one or two of the three distinct catalytic \( \beta \) subunits are disabled and carry remnants of their N-terminal propeptides4 (Table 1). These results indicate that the \( \beta_1 \) and \( \beta_2 \) proteolytic activities are not essential for cell survival. By contrast, the T1A mutation in subunit \( \beta_5 \) has been reported to be lethal or nearly so1,13. Viability is restored if the \( \beta_5\)-T1A subunit has its propeptide (pp) deleted but expressed separately in trans (\( \beta_5\)-T1A pp trans), although substantial phenotypic impairment remains1,15,16 (Table 1). Our present crystallographic analysis of the \( \beta_5\)-T1A pp trans mutant demonstrates that the mutation per se does not structurally alter the catalytic active site and that the trans-expressed \( \beta_5 \) propeptide is not bound in the \( \beta_5 \) substrate-binding channel (Supplementary Fig. 1a).

The extremely weak growth of the \( \beta_5\)-T1A pp cis described by Chen and Hochstrasser1 compared with the inviability reported by Heinemeyer et al.1,15 prompted us to analyse this discrepancy. Sequencing of the plasmids, testing them in both published yeast strain backgrounds and site-directed mutagenesis revealed that the \( \beta_5\)-T1A mutant pp cis is viable, but suffers from a marked growth defect that requires extended incubation of 4–5 days for initial colony formation (Table 1 and Supplementary Methods). We also identified an additional point mutation K81R in subunit \( \beta_5 \) that was present in the allele used in ref. 1. This single amino-acid exchange is located at the interface of the subunits \( \gamma_4, \beta_4 \) and \( \beta_5 \) (Supplementary Fig. 1b) and might weakly promote CP assembly by enhancing inter-subunit contacts. The slightly better growth of the \( \beta_5\)-T1A-K81R mutant allowed us to solve the crystal structure of a yeast proteasome (\( \gamma \)CP) with the \( \beta_5\)-T1A mutation, which is discussed in the following section (for details see Supplementary Note 1).

Propeptide conformation and triggering of autolysis. In the final steps of proteasome biogenesis, the propeptides are autocatalytically cleaved from the mature \( \beta \)-subunit domains1. For subunit \( \beta_1 \), this process was previously inferred to require that the propeptide residue at position (-2) of the subunit precursor occupies the S1 specificity pocket of the substrate-binding channel formed by amino acid 45 (for details see Supplementary Note 2)3. Furthermore, it was observed that the prosegment forms an antiparallel \( \beta \)-sheet in the active site, and that Gly(-1) adopts a \( \gamma \)-turn conformation, which by definition is characterized by a hydrogen bond between Leu(-2)O and Thr1NH (ref. 5). Here we again analysed the \( \beta_1\)-T1A mutant crystallographically but in addition determined the structures of the \( \beta_2\)-T1A single and \( \beta_1\)-T1A-\( \beta_2\)-T1A double mutants (Protein Data Bank (PDB) entry codes are provided in Supplementary Table 1). In subunit \( \beta_1 \), we found that Gly(-1) indeed forms a sharp turn, which relaxes on prosegment cleavage (Fig. 1a and Supplementary Fig. 2a). However, the \( \gamma \)-turn conformation and the associated hydrogen bond initially proposed is for geometrical and chemical reasons inappropriate and would not perfectly position the carbonyl carbon atom of Gly(-1) for nucleophilic attack by Thr1. Regarding the \( \beta_2 \) propeptide, Thr(-2) occupies the S1 pocket but is less deeply anchored compared with Leu(-2) in \( \beta_1 \), which might be due to the rather large \( \beta_2\)-S1 pocket created by Gly45. Thr(-2) positions Gly(-1)O via hydrogen bonding (~2.8 Å) in a perfect trajectory for the nucleophilic attack by Thr1O\( _\gamma \) (Fig. 1b and Supplementary Fig. 2b). Next, we examined the position of the \( \beta_5 \) propeptide in the \( \beta_5\)-T1A-K81R mutant. Surprisingly, Gly(-1) is completely extended and forces the histidine side chain at position (-2) to occupy the S2 instead of the S1 pocket, thereby disrupting the antiparallel \( \beta \)-sheet. Nonetheless, the carbonyl carbon of Gly(-1) would be ideally placed for nucleophilic attack by Thr1O\( _\gamma \) (Fig. 1c and Supplementary Fig. 2c,d). As the K81R mutation is located far from the active site (Thr1C\( ^{2=7} \)-Arg81C\( ^{2=7} \), 24 Å), any influence on propeptide conformation can be excluded. Instead, the plasticity of the \( \beta_5 \) S1 pocket caused by the rotational flexibility of Met45 might prevent stable accommodation of His(-2) in the S1 site and thus also promote its immediate release after autolysis.

Processing of \( \beta \)-subunit precursors requires deprotonation of Thr1OH; however, the general base initiating autolysis is unknown. Remarkably, eukaryotic proteasomal \( \beta_5 \) subunits bear a His residue in position (-2) of the propeptide (Supplementary Fig. 3a). As histidine commonly functions as a proton shuttle in the catalytic triads of serine proteases17, we investigated the role of His(-2) in processing of the \( \beta_5 \) propeptide by exchanging it for Asn, Lys, Phe and Ala. All yeast mutants were viable at 30 °C,
Table 1 | Growth phenotypes and status of autolysis and catalysis of mutants.

| Mutant                      | Viability | Temperature sensitivity | Autolysis state of the mutant subunit | Activity of the mutant subunit |
|-----------------------------|-----------|-------------------------|---------------------------------------|---------------------------------|
| WT                          | ++ + +    | +                       | +                                    | ++ + +                          |
| β1-T1A (ref. 13)            | ++ + +    | +                       | ND                                   | −                               |
| β2-T1A (ref. 13)            | ++ + +    | +                       | ND                                   | −                               |
| β1-T1A β2-T1A (ref. 13)     | ++ + +    | +                       | −                                    | −                               |
| β5-T1A                      | ++ + +    | +                       | ND                                   | −                               |
| β5-H(-2)A-T1A               | + / −     | ND                      | −                                    | −                               |
| β5-H(-2)T-T1A               | + / −     | ND                      | −                                    | −                               |
| β5-H(-2)L-T1A               | + / −     | ND                      | −                                    | −                               |
| β5-T1A, pp trans, natIΔ     | + / −     | ND                      | −                                    | −                               |
| β5-T1A-K81R                 | +         | ND                      | −                                    | −                               |
| β5-H(-2)A-T1A-K81R          | + / −     | ND                      | −                                    | −                               |
| β5-H(-2)T-T1A-K81R          | + / −     | ND                      | −                                    | −                               |
| β5-H(-2)L-T1A-K81R          | +         | ND                      | −                                    | −                               |
| β5-H(-2)A                   | + + + +    | +                       | +                                    | + + + +                         |
| β5-H(-2)K                   | + + + +    | +                       | +                                    | + + + +                         |
| β5-H(-2)F                   | + + + +    | +                       | +                                    | + + + +                         |
| β5-H(-2)N                   | + + + +    | +                       | +                                    | + + + +                         |
| β5pp-β (ref. 18)            | + / −     | ND                      | −                                    | −                               |
| β2-T(-2)V                   | + + + +    | +                       | −                                    | −                               |
| β5-L(-49S)-K33A (ref. 13)   | +         | + + + +                 | −                                    | −                               |
| β5-K33A, pp trans           | +         | + + + +                 | +                                    | −                               |
| β5-F(-45S)-K33R (ref. 13)   | +         | + + + +                 | +                                    | −                               |
| β5-DI7N                     | + / −     | ND                      | −                                    | −                               |
| β5-DI7N, pp trans           | +         | + + + +                 | + / −                                | −                               |
| β5-DI66N                    | +         | + + + +                 | +                                    | −                               |
| β5-DI66N, pp trans          | + / −     | ND                      | −                                    | −                               |
| β5-TIS                      | + + + +    | +                       | +                                    | + + + +                         |
| β5-TIC                      | +         | + + + +                 | +                                    | −                               |

ND, not determined.

*The autolysis state was assessed by purification and crystallization of the mutant proteasomes.

*Purification of this mutant proteasome was not possible.

Figure 1 | Conformation of proteasomal propeptides. (a) Structural superposition of the β1-T1A propeptide and the matured WT β1 active-site Thr1. Only the residues (-5) to (-1) of the β1-T1A propeptide are displayed. The major determinant of the S1 specificity pocket, residue 45, is depicted. Note the tight conformation of Gly(-1) and Ala1 before propeptide removal (G(-1) turn; cyan double arrow) compared with the relaxed, processed WT active-site Thr1 (red double arrow). The black arrow indicates the attack of Thr(-2)OH on the carbonyl carbon atom of Gly(-1). (b) Structural superposition of the β1-T1A propeptide and the β2-T1A propeptide highlights subtle differences in their conformations, but illustrates that Ala1 and Gly(-1) match well. Thr(-2)OH is hydrogen-bonded to Gly(-1)O (2.8 Å; black dashed line). The major determinant of the S1 specificity pocket, residue 45, is depicted. (c) Structural superposition of the β1-T1A, the β2-T1A and the β5-T1A-K81R propeptide remnants depict their differences in conformation. While residue (-2) of the β1 and β2 prosegments fit the S1 pocket, His(-2) of the β5 propeptide occupies the S2 pocket. Nonetheless, in all mutants the carbonyl carbon atom of Gly(-1) is ideally placed for the nucleophilic attack by Thr107. The hydrogen bond between Thr(-2)OH and Gly(-1)O (2.8 Å) is indicated by a black dashed line.

but suffered from growth defects at 37 °C with the H(-2)N and H(-2)F mutants being most affected (Supplementary Fig. 3b and Table 1). In agreement, the chymotrypsin-like (ChT-L) activity of H(-2)N and H(-2)F mutant γCPs was impaired in situ and in vitro (Supplementary Fig. 3c). Structural analyses revealed that the propeptides of all mutant γCPs shared residual 2Fo-Fc electron densities. Gly(-1) and Phe/Lys(-2) were visualized at low occupancy, while Ala/Asn(-2) could not be assigned. This observation indicates a mixture of processed and unprocessed β5 subunits and partially impaired autolysis18, thereby excluding any essential role of residue (-2) as the general base.

Next, we examined the effect of residue (-2) on the orientation of the propeptide by creating mutants that combine the T1A (K81R) mutation(s) with H(-2)L, H(-2)T or H(-2)A substitutions. Leu(-2) is encoded in the yeast β1 subunit precursor (Supplementary Fig. 3a); Thr(-2) is generally part of
that neither binding of residue (-2) to the S1 pocket nor formation of the antiparallel β-sheet is essential for autolysis of the propeptide.

Next, we determined the crystal structure of a chimeric γCP having the yeast β1-propeptide replaced by its β5 counterpart. Although we observed fragments of 2F₀–F₁ electron density in the β1 active site, the data were not interpretable. Bearing in mind that in contrast to Thr(-2) in β2, Leu(-2) in subunit β1 is not conserved among species (Supplementary Fig. 3a), we created a β2-T(-2)V proteasome mutant. As proven by the β2-T1A crystal structures, Thr(-2) hydrogen bonds to Gly(-1)O. Although this interaction was not observed for the β5-H(-2)T-T1A mutant (Fig. 2c and Supplementary Fig. 4c,i), exchange of Thr(-2) by Val in β2, a conservative mutation regarding size but drastic with respect to polarity, was found to inhibit maturation of this subunit (Fig. 2d and Supplementary Fig. 4e,i). Notably, the 2F₀–F₁ electron-density map displays a different orientation for the β2 propeptide than has been observed for the β2-T1A proteasome. In particular, Val(-2) is displaced from the S1 site and Gly(-1) is severely shifted (movement of the carbonyl oxygen atom of 3.8 Å), thereby preventing nucleophilic attack of Thr1 on the carbonyl carbon atom of Gly(-1). For all panels stereo views are provided in Supplementary Fig. 4g-j.

The active site of the proteasome. Proton shuttling from the proteasomal active site Thr1OH to Thr1NH₂ via a nucleophilic water molecule was suggested to initiate peptide-bond hydrolysis. However, in the immature particle Thr1NH₂ is blocked by the propeptide and cannot activate Thr1O². Instead, Lys33NH₂, which is in hydrogen-bonding distance to Thr10⁴ (2.7 Å) in all catalytically active β subunits (Fig. 3a,b), was proposed to serve as the proton acceptor. Owing to its likely protonation at neutral pH, however, it was assumed not to act as the general base. A catalytic tetrad model involving Thr1OH, Thr1NH₂, Lys33NH₂ and Asp17O⁶, as well as a nucleophilic water molecule as the proton shuttle appeared to accommodate all possible views of the proteasomal active site. Twenty years later, with a plethora of γCP X-ray structures in hand, we decided to re-examine the active site of the proteasome and to resolve the uncertainty regarding the nature of the general base. Mutation of β5-Lys33 to Ala causes a strongly deleterious phenotype, and previous structural and biochemical analyses confirmed that this is caused by failure of propeptide cleavage, and consequently, lack of ChT-L activity. The phenotype of the β5-K33A mutant was however less pronounced than for the β5-T1A-K81R yeast (Fig. 4a). This discrepancy in growth was traced to an additional point mutation L(-49)S in the β5 proteasome mutant (see also Supplementary Note 1). Structural comparison of the β5-L(-49)S-K33A and β5-T1A-K81R active sites revealed that mutation of Lys33 to Ala causes a cavity that is filled with Thr1 and the remnant propeptide. This structural alteration destroys active-site integrity and abolishes catalytic activity of the β5 active site (Supplementary Fig. 5a). Additional proof for the key function of Lys33 was obtained from the β5-K33A mutant, with the propeptide expressed separately from the main subunit (pp trans). The Thr1 N terminus of this mutant is not blocked by the propeptide, yet its catalytic activity is reduced by ~83% (Supplementary Fig. 6b). Consistent with this, the crystal structure of the β5-K33A pp trans mutant in complex with carfilzomib only showed partial occupancy of the ligand at the β5 active sites (Supplementary Fig. 5b and Supplementary Table 1). Since no acetylation of the Thr1 N terminus was observed for the
The reduced reactivity towards substrates and inhibitors indicates that Lys33NH₂, rather than Thr1NH₂, deprotonates and activates Thr1OH. Furthermore, the crystal structure of the β5-K33A pp trans mutant without inhibitor revealed that Thr1OH is hydrogen-bonded to Lys33NH₂ (2.7 Å), which in turn interacts with Asp17O⁶. The Thr1 N terminus is engaged in hydrogen bonds with Ser129O', the carbonyl oxygen of residue 168, Ser169O' and Asp166O'.

The orientations of the active-site residues involved in hydrogen bonding are strictly conserved in each proteolytic centre, as shown by superposition of the β subunits. Structural superposition of the WT β5 and the β5-K33A pp trans mutant active site. In the latter, a water molecule (red sphere) is found at the position where in the WT structure the side chain amine group of Lys33 is located. Similarly to Lys33, the water molecule hydrogen bonds to Arg19O, Asp17O’ and Thr1OH. Note, the strong interaction with the water molecule causes a minor shift of Thr1, while all other active-site residues remain in place.

Proposed chemical reaction mechanism for autocatalytic precursor processing and proteolysis in the proteasome. The active-site Thr1 is depicted in blue, the propeptide segment and the peptide substrate are coloured in green, whereas the scissile peptide bond is highlighted in red. Autolysis (left set of structures) is initiated by deprotonation of Thr1OH via Lys33NH₂ and the formation of a tetrahedral transition state. The strictly conserved oxyanion hole Gly47NH stabilizing the negatively charged intermediate is illustrated as a semicircle. Collapse of the transition state frees the Thr1 N terminus (by completing an N-to-O acyl shift of the propeptide), which is subsequently protonated by Asp166OH via Ser129OH. Next, Thr1NH₂ polarizes a water molecule for the nucleophilic attack of the acyl-enzyme intermediate. On hydrolysis of the latter, the active-site Thr1 is ready for catalysis (right set of structures). Substrate processing starts with nucleophilic attack of the carbonyl carbon atom of the scissile peptide bond. The charged Thr1 N terminus may engage in the orientation of the amide moiety and donate a proton to the emerging N terminus of the C-terminal cleavage product. The resulting deprotonated Thr1NH₂ finally activates a water molecule for hydrolysis of the acyl-enzyme.

β5-K33A pp trans apo crystal structure⁴,¹⁶, the reduced reactivity towards substrates and inhibitors indicates that Lys33NH₂, rather than Thr1NH₂, deprotonates and activates Thr1OH. Furthermore, the crystal structure of the β5-K33A pp trans mutant without inhibitor revealed that Thr1O’ strongly coordinates a well-defined water molecule (≈2 Å; Fig. 3c and Supplementary Fig. 5c,d). This water hydrogen bonds also to Arg19O (≈3.0 Å) and Asp17O’ (≈3.0 Å), and thereby presumably enables residual activity of the mutant. Remarkably, the solvent molecule occupies the position normally taken by Lys33NH₂ in the WT proteasome structure (Fig. 3c), further corroborating the essential role of Lys33 as the general base for autolysis and proteolysis. Conservative substitution of Lys33 by Arg delays autolysis of the β5 precursor and impairs yeast growth (for details see Supplementary Note 1). While Thr1 occupies the same position as in WT yCPs, Arg33 is unable to hydrogen...
bond to Asp17, thereby inactivating the β5 active site2,4 (Supplementary Fig. 5e).

The conservative mutation of Asp17 to Asn in subunit β5 of the yCP also provokes a severe growth defect (Supplementary Note 1, Supplementary Fig. 6a and Table 1). Notably, only with the additional point mutation L(-49)S present in the β5 propeptide could we purify a small amount of the β5-D17N mutant yCP. As determined by crystallographic analysis, this mutant β5 subunit was partially processed (Table 1) but displayed impaired reactivity towards the proteasome inhibitor carfilzomib compared with the subunits β1 and β2, and with WT β5 (Supplementary Fig. 7a). In contrast to the cis-construct, expression of the β5 propeptide in trans allowed straightforward isolation and crystallization of the D17N mutant proteasome. The ChT-L activity of the β5-D17N pp in trans CP towards the canonical β5 model substrates N-succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC) and carboxybenzyl-Gly-Gly-para-nitroanilide (Z-GGL-pNA) was severely reduced (Supplementary Fig. 6b), confirming that Asp17 is of fundamental importance for the catalytic activity of the mature proteosome. Even though the β5-D17N pp trans yCP crystal structure appeared identical to the WT yCP (Supplementary Fig. 7b), the co-crystal structure with the ω', β' epoxyketone inhibitor carfilzomib visualized only partial occupancy of the ligand in the β5 active site (Supplementary Fig. 7a). This observation is consistent with a strongly reduced reactivity of β5-Thr1 and the crystal structure of the β5-D17N pp cis mutant in complex with carfilzomib. Autolysis and residual catalytic activity of the β5-D17N mutants may originate from the carbonyl group of Asn17, which albeit to a lower degree still can polarize Lys33 for the activation of Thr1. In agreement, an E17A mutant in the proteosomal β-subunit of the archaeon Thermoplasma acidophilum prevents autolysis and catalysis21. Strikingly, although the X-ray data on the β5-D17N mutant with the propeptide expressed in cis and in trans looked similar, there was a pronounced difference in their growth phenotypes observed (Supplementary Fig. 6a and Supplementary Fig. 7b).

On the basis of these results, we propose that CPs from all domains of life use a catalytic triad consisting of Thr1, Lys33 and Asp/Glu17 for both autocatalytic precursor processing and proteolysis (Fig. 3d). This model is also consistent with the fact that no defined water molecule is observed in the mature WT proteasomal active site that could shuttle the proton from Thr1O to Thr1NH2.

To explore this active-site model further, we exchanged the conserved Asp166 residue for Asn in the yeast β5 subunit. Asp1660 is hydrogen-bonded to Thr1NH2 via Ser129OH and Ser169OH, and therefore was proposed to be involved in catalysis2. The β5-D166N pp cis yeast mutant is significantly impaired in growth and its ChT-L activity is drastically reduced (Supplementary Fig. 6a,b and Table 1). X-ray data on the β5-D166N mutant indicate that the β5 propeptide is hydrolysed, but due to reorientation of Ser129OH, the interaction with Asn1660 is disrupted (Supplementary Fig. 8a). Instead, a water molecule is bound to Ser129OH and Thr1NH2 (Supplementary Fig. 8b), which may enable precursor processing. The hydrogen bonds involving Ser169OH are intact and may account for residual substrate turnover. Soaking the β5-D166N crystals with carfilzomib and MG132 resulted in covalent modification of Thr1 at high occupancy (Supplementary Fig. 8c). In the carfilzomib complex structure, Thr1O2 and Thr1N incorporate into a morpholine ring structure and Ser129 adopts its WT-like orientation. In the MG132-bound state, Thr1N is unmodified, and we again observe that Ser129 is hydrogen-bonded to a water molecule instead of Asn166. Whereas Asn can to some degree replace Asp166 due to its carbonyl group in the side chain, Ala at this position was found to prevent both autolysis and catalysis21. These results suggest that Asp166 and Ser129 function as a proton shuttle and affect the protonation state of Thr1N during autolysis and catalysis.

Substitution of the active-site Thr1 by Cys. Mutation of Thr1 to Cys inactivates the 20S proteasome from the archaean T. acidophilum21. In yeast, this mutation causes a strong growth defect (Fig. 4a and Table 1), although the propeptide is hydrolysed, as shown here by its X-ray structure. In one of the two β5 subunits, however, we found the cleaved propeptide still bound in the substrate-binding channel (Fig. 4c). His(-2) occupies the S2 pocket like observed for the β5-T1A-K81R mutant, but in contrast to the latter, the propeptide in the T1C mutant adopts an antiparallel β-sheet conformation as known from inhibitors like MG132 (Fig. 4c–e and Supplementary Fig. 9b). On the basis of the phenotype of the T1C mutant and the propeptide remnant identified in its active site, we suppose that autolysis is retarded and may not have been completed before crystallization. Owing to the unequal positions of the two β5 subunits within the CP in the crystal lattice, maturation and propeptide displacement may occur at different timescales in the two subunits.

Despite propeptide hydrolysis, the β5-T1C active site is catalytically inactive (Fig. 4b and Supplementary Fig. 9a). In agreement, soaking crystals with the CP inhibitors bortezomib or carfilzomib modifies only the β1 and β2 active sites, while leaving the β5-T1C proteolytic centres unmodified even though they are only partially occupied by the cleaved propeptide remnant. Moreover, the structural data reveal that the thiol group of Cys1 is rotated by 74° with respect to the hydroxyl side chain of Thr1 (Fig. 4f and Supplementary Fig. 9b). This presumably results from the larger radius of the sulfur atom compared with oxygen. Consequently, the hydrogen bond bridging the active-site nucleophile and Lys33 in WT CPs is broken with Cys1. Notably, the 2Fo–Fc electron-density map of the T1C mutant also indicates that Lys33NH2 is disordered. Together, these observations suggest that efficient peptide-bond hydrolysis requires that Lys33NH2 hydrogen bonds to the active-site nucleophile.

The benefit of Thr over Ser as the active-site nucleophile. All proteasomes strictly employ threonine as the active-site residue instead of serine. To investigate the reason for this singularity, we analysed a β5-T1S mutant, which is viable but suffers from growth defects (Fig. 4a and Table 1). Activity assays with the β5-specific substrate Suc-LLVY-AMC demonstrated that the ChT-L activity of the T1S mutant is reduced by 40–45% compared with WT proteasomes depending on the incubation temperature (Fig. 4b and Supplementary Fig. 9c). By contrast, turnover of the substrate Z-GGL-pNA, used to monitor ChT-L activity in situ but in a less quantitative fashion, is not detectably impaired (Supplementary Fig. 9a). Crystal structure analysis of the β5-T1S mutant confirmed precursor processing (Fig. 4g), and ligand–complex structures with bortezomib and carfilzomib unambiguously corroborated the reactivity of Ser1 (Fig. 5).

However, the apo crystal structure revealed that Ser1O2 is turned away from the substrate-binding channel (Fig. 4g). Compared with Thr1O to WT CP structures, Ser1O2 is rotated by 60°. This renders it unavailable for direct nucleophilic attack onto incoming substrates and first requires its reorientation, which is expected to delay substrate turnover. Because both conformations of Ser1O2 are hydrogen-bonded to Lys33NH2 (Fig. 4h), the relay system is capable of hydrolysing peptide substrates, albeit at lower rates compared with Thr1. The active-site residue Thr1 is fixed in its position, as its methyl group is engaged in hydrophobic interactions with Thr3
and Ala46 (Fig. 4h). Consequently, the hydroxyl group of Thr1 requires no reorientation before substrate cleavage and is thus more catalytically efficient than Ser1. In agreement, at an elevated growing temperature of 37 °C the T1S mutant is unable to grow (Fig. 4a). In vitro, the mutant proteasome is less susceptible to proteasome inhibition by bortezomib (3.7-fold) and carfilzomib (1.8-fold; Fig. 5). Nevertheless, inhibitor complex structures indicate identical binding modes compared with the WT yCP structures, with the same inhibitors22,23. Notably, the affinity of the tetrapeptide carfilzomib is less impaired, as it is better stabilized in the substrate-binding channel than the dipeptide bortezomib, which lacks a defined P3 site and has only a few interactions with the surrounding protein. Hence, the mean residence time of carfilzomib at the active site is prolonged and the probability to covalently react with Ser1 is increased. Considered together, these results provide a plausible explanation for the invariance of threonine as the active-site nucleophile in proteasomes in all three domains of life, as well as in proteasome-like proteases such as HslV (ref. 24).

Figure 4 | The proteasome favours threonine as the active-site nucleophile. (a) Growth tests by serial dilution of WT and pre2 (β5) mutant yeast cultures reveal growth defects of the active-site mutants under the indicated conditions after 2 days (2 d) of incubation. (b) Purified WT and mutant proteasomes were tested for their chymotrypsin-like activity (β5) using the substrate Suc-LLVY-AMC. Relative fluorescence units were measured in triplicate after 1 h of incubation at room temperature and are given as mean values. S.d.’s are indicated by error bars. (c) Illustration of the 2F₀–F₀ electron-density map (blue mesh contoured at 1σ) for the β5-T1C propeptide fragment. The prosegment is cleaved but still bound in the substrate-binding channel. Notably, His(-2) does not occupy the S1 pocket formed by Met45, similar to what was observed for the β5-T1A-K81R mutant. (d) Structural superposition of the β5-T1A-K81R and the β5-T1C mutant subunits onto the WT β5 subunit. (e) Structural superposition of the β5-T1C propeptide onto the β1-T1A active site (blue) and the WT β5 active site in complex with the proteasome inhibitor MG132 (ref. 30). The inhibitor as well as the propeptides adopt similar conformations in the substrate-binding channel. (f) Structural superposition of the WT β5 and β5-T1C mutant active sites illustrates the different orientations of the hydroxyl group of Thr1 and the thiol side chain of Cys1. The SH group is rotated by 74° compared with the OH group. (g) Structural superposition of the WT β5 and β5-T1S mutant active sites reveals different orientations of the hydroxyl groups of Thr1 and Ser1, respectively. The 2F₀–F₀ electron-density map for Ser1 (blue mesh contoured at 1σ) is illustrated. (h) The methyl group of Thr1 is anchored by hydrophobic interactions with Ala46Cβ and Thr3Cβ. Ser1 lacks this stabilization and is therefore rotated by 60°.
reactivity of Ser1 (right panel). The 2 of the bortezomib or carfilzomib. demonstrate that mutation of Thr1 to Ser does not affect the binding mode complex structures (inhibitor in grey; Thr1 in black) are superimposed and to inhibition by bortezomib and carfilzomib using the substrate Suc-LLVY-

Escherichia coli heterologously expressed in are dispensable for archaeal proteasome assembly, at least when 45 min before substrate addition (final concentration: 200 proteasomes (final concentration: 66 nM) were incubated with inhibitor for 45 min before substrate addition (final concentration: 200 µM). Structures of the β5-T1S mutant in complex with both ligands (green) prove the reactivity of Ser1 (right panel). The 2F₀-Fc electron-density maps (blue mesh) for Ser1 (brown) and the covalently bound ligands (green; only the P1 site (Leu1) is shown) are contoured at 1σ. The WT proteasome:inhibitor complex structures (inhibitor in grey; Thr1 in black) are superimposed and demonstrate that mutation of Thr1 to Ser does not affect the binding mode of bortezomib or carfilzomib.

Discussion

The 20S proteasome CP is the major non-lysosomal protease in eukaryotic cells, and its assembly is highly organized. The β-subunit propeptides, particularly that of β5, are key factors that help drive proper assembly of the CP complex. In addition, they prevent irreversible inactivation of the Thr1 N terminus by N-acetylation. By contrast, the prosegments of β subunits are dispensable for archaeal proteasome assembly, at least when heterologously expressed in Escherichia coli. In eukaryotes, deletion of or failure to cleave the β1 and β2 propeptides is well tolerated. However, removal of the β5 prosegment or any interference with its cleavage causes severe phenotypic defects. These observations highlight the unique function and importance of the β5 propeptide as well as the β5 active site for maturation and function of the eukaryotic CP.

Here we have described the atomic structures of various β5-T1A mutants, which allowed for the first time visualization of the residual β5 propeptide. Depending on the (-2) residue we observed various propeptide conformations, but Gly(-1) is in all structures perfectly located for the nucelophilic attack by Thr1O⁺, although it does not adopt the tight turn observed for the prosegment of subunit β1. From these data we conclude that only the positioning of Gly(-1) and Thr1 as well as the integrity of the proteasomal active site are required for autolysis. In this regard, inappropriate N-acetylation of the Thr1 N terminus cannot be removed by Thr1O⁺ due to the rotational freedom and flexibility of the acetyl group. The propeptide needs some anchoring in the substrate-binding channel to properly position Gly(-1), but this seems to be independent of the orientation of residue (-2).

Autolytic activation of the CP constitutes one of the final steps of proteasome biogenesis, but the trigger for propeptide cleavage had remained enigmatic. On the basis of the numerous CP:ligand complexes solved during the past 18 years and in the current study, we provide a revised interpretation of proteasome active-site architecture. We propose a catalytic triad for the active site of the CP consisting of residues Thr1, Lys33 and Asp/Glu17, which are conserved among all proteolytically active eukaryotic, bacterial and archaeal proteasome subunits. Lys33NH₂ is expected to act as the proton acceptor during autocatalytic removal of the propeptides, as well as during substrate proteolysis, while Asp17O⁻ orients Lys33NH₂ and makes it more prone to protonation by raising its pKₐ (hydrogen bond distance: Lys33NH₂⁻ –Asp17O⁻: 2.9 Å). Analogously to the proteasome, a Thr-Lys-Asp triad is also found in ω-asparaginase. Thus, specific protein surroundings can significantly alter the chemical properties of amino acids such as Lys to function as an acid–base catalyst.

In this new view of the proteasomal active site, the positively charged Thr1NH₃⁺-terminus hydrogen bonds to the amide nitrogen of incoming peptide substrates and stabilizes as well as activates them for the endoproteolytic cleavage by Thr1O⁺ (Fig. 3d). Consistent with this model, the positively charged Thr1 N terminus is engaged in hydrogen bonds with inhibitory compounds like fellutamide B (ref. 29), α-ketoamides, homobelactosin C (ref. 31) and salinosporamide A (ref. 32). Furthermore, opening of the β-lactone compound omuralide by Thr1 creates a C3-hydroxy group, whose proton originates from Thr1NH₃⁺. The resulting uncharged Thr1NH₂ is hydrogen-bridged to the C3-OH group. In agreement, acetylation of the Thr1 N terminus irreversibly blocks hydrolytic activity, and binding of substrates is prevented for steric reasons. By acting as a proton donor during catalysis, the Thr1 N terminus may also favour cleavage of substrate peptide bonds (Fig. 3d). In all proteases, collapse of the tetrahedral transition state results in selective breakage of the substrate amide bond, while the covalent interaction between the substrate and the enzyme persists. Cleavage of the scissile peptide bond requires protonation of the emerging free amine, and in the proteasome, the Thr1 amine group is likely to assume this function. Analogously, Thr1NH₃⁺ might promote the bivalent reaction mode of epoxyketone inhibitors by protonating the epoxide moiety to create a positively charged trivalent oxygen atom that is subsequently nucleophilically attacked by Thr1NH₂.

During autolysis the Thr1 N terminus is engaged in a hydroxoyoxazolidine ring intermediate (Fig. 3d), which is unstable and short-lived. Breakdown of this tetrahedral transition state releases the Thr1 N terminus that is protonated by aspartic acid 166 via Ser129OH₂ to yield Thr1NH₂⁻. The residues Ser129 and Asp166 are expected to increase the pKₐ value of Thr1N, thereby favouring its charged state. Consistent with playing an essential role in proton shuttling, the mutation D166A prevents autolysis of the archaeal CP and the exchange D166N impairs catalytic activity of the yeast CP about 60%. The mutation D166N lowers the pKₐ of Thr1N, which is thus more likely to exist in the uncharged deprotonated state (Thr1NH₂⁻). This renders the N terminus less suitable to stabilize substrates and to protonate the first cleavage product during catalysis, although it favours its
ability to act as a nucleophile. This interpretation agrees with the strongly reduced catalytic activity of the β5-D166N mutant on the one hand, and the ability to react readily with carfilzomib on the other. Hence, the protease can be viewed as having a second triad that is essential for efficient proteolysis. While Lys33NH₂ and Asp170⁴ are required to deprotonate the Thr1 hydroxyl side chain, Ser129OH and Asp166OH serve to protonate the N-terminal amine group of Thr1.

In accord with the proposed Thr1–Lys33–Asp17 catalytic triad, crystallographic data on the proteolytically inactive β5-T1C mutant demonstrate that the interaction of Lys33NH₂ and Cys1 is broken. Consequently, efficient substrate turnover or covalent modification by ligands is prevented. However, owing to Cys being a strong nucleophile, the peptidopeptide can still be cleaved off over time. While only one single turnover is necessary for autorolysis, continuous enzymatic activity is required for significant and detectable substrate hydrolysis. Notably, in the Tn7 hydroxase penicillin acylase, substitution of the catalytic N-terminal Ser residue by Cys also inactivates the enzyme but still enables precursor processing⁴⁴.

To investigate why the CP specifically employs threonine as its active-site residue, we used a β5-T1S mutant of the γCP and characterized it biochemically and structurally. Activity assays with the β5-T1S mutant revealed reduced turnover of Suc-LLVY-AMC. We also observed slightly lower affinity of the β5-T1S mutant γCP for the Food and Drug Administration-approved proteasome inhibitors bortezomib and carfilzomib. Structural analyses support these findings with the T1S mutant and provide an explanation for the strict use of Thr residues in proteasomes. Thr1 is well anchored in the active site by hydrophobic interactions of its C⁷ carbon methyl group with Ala46 (C⁸), Lys33 (carbon side chain) and Thr3 (C⁹). Notably, proteolytically active proteasome subunits from archaea, yeast and mammals, including constitutive, immuno- and thymoproteasome subunits, either encode Thr or Ile at position 3, indicating the importance of the C⁷ for fixing the position of the nucleophilic Thr1. In contrast to Thr1, the hydroxyl group of Ser1 occupies the position of the Thr1 methyl side chain in the WT enzyme, which requires its reorientation relative to the substrate to allow cleavage (Fig. 4g,h).

Notably, in the threonine aspartate Taspase1, mutation of the active-site Thr234 to Ser also places the side chain in the position of the methyl group of Thr234 in the WT, thereby reducing catalytic activity⁴⁴. Similarly, although the serine mutant is active, threonine is more efficient in the context of the proteasome active site. The greater suitability of threonine for the proteasome active site, which has been noted in biochemical as well as in kinetic studies⁴⁵, constitutes a likely reason for the conservation of the Thr1 residue in all proteasomes from bacteria to eukaryotes.

Methods

Yeast mutagenesis. Site-directed mutagenesis was performed by standard techniques using oligonucleotides listed in Supplementary Table 2. The pre2/Δα3 (β5) mutant alleles in the centromeric, TRP1 or LEU2-marked shuttle vectors YCP22 and pKS15, respectively, were verified by sequencing and subsequently introduced into the yeast strains MYH784 (ref. 1) or YWH20 (ref. 13), which express WT pre2 from a YRA3-marked plasmid. Counter-selection against the YRA3 marker with 5-fluoroorotic acid yielded strains expressing only the mutant forms of β5.

The strain producing a processed β5-T1A variant and the β5 propeptide in trans is a derivative of YWH212 (ref. 15). It carries an additional deletion of the NATI gene to avoid N-acetylation of Ala1; this strain exhibits extremely slow growth rates and served for crystallographic analysis only. All strains used in this study are listed in Supplementary Table 3.

Purification of yeast proteasomes. Yeast strains were grown in 18-L cultures at 30 °C in YPD into early stationary phase, and the γCPs were purified according to published procedures⁴². In brief, 120 g yeast cells were solubilized in 150 ml 50 mM KH₂PO₄/K₂HPO₄ buffer (pH 7.5) and disrupted with a French press. Cell debris were removed by centrifugation for 30 min at 21,000 r.p.m. (4 °C). The resulting supernatant was filtered and ammonium sulfate (saturated solution) was added to a final concentration of 30% (v/v). This solution was loaded on a Phenyl Sepharose 6 Fast Flow column (GE Healthcare) pre-equilibrated with 1 M ammonium sulfate in 20 mM KH₂PO₄/K₂HPO₄ (pH 7.5). CPs were washed by applying a linear gradient from 1 to 0 M ammonium sulfate. Proteasome-containing fractions were pooled and loaded onto a hydroxyapatite column (Bio-Rad) equilibrated with 20 mM KH₂PO₄/K₂HPO₄ (pH 7.5). Elution of the CPs was achieved by increasing the phosphate buffer concentration from 20 to 500 mM. Anion-exchange chromatography (Resource Q column; GE Healthcare), elution gradient from 0 to 500 mM sodium chloride in 20 mM Tris-HCl (pH 7.5) and subsequent size-exclusion chromatography (Superose 6 10/300 GL; GE Healthcare), 20 mM Tris-HCl (pH 7.5) and 150 mM NaCl resulted in pure CPs for crystallization and activity assays.

Fluorescence-based activity assay. Cht-L (β5) activity of CPs was monitored by fluorescence spectroscopy using the model substrate Suc-LLVY-AMC. Purified γCPs (66 nM in 100 mM Tris-HCl, pH 7.5) were incubated with 300 μM substrate at room temperature or 37 °C. The reaction was stopped by diluting the samples 1:10 in 20 mM Tris-HCl, pH 7.5. AMC fluorophores released by proteasomal activity were measured in triplicate with a Varian Cary Eclipse Fluorescence Spectrophotometer (Agilent Technologies) at λex = 360 nm and λem = 460 nm.

Inhibition assays. Purified γCPs were mixed with dimethylsulfoxide as a control or serial dilutions of inhibitor and incubated for 45 min at room temperature. A final concentration of γCP of 66 nM was used. After addition of the peptide sub- strate Suc-LLVY-AMC to a final concentration of 200 μM and incubation for 1 h at room temperature, the reaction was stopped by diluting the samples 1:10 in 20 mM Tris-HCl, pH 7.5. AMC fluorophores released by residual proteasomal activity were measured in triplicate at λex = 360 nm and λem = 460 nm. Relative fluorescence units were normalized to the dimethylsulfoxide-treated control. The calculated residual activities were plotted against the logarithm of the applied inhibitor concentration and fitted with GraphPad Prism 5. The IC₅₀ value, the ligand concentration that leads to 50% inhibition of the enzymatic activity, was deduced from the fitted data.

Cryocristallization and structure determination. Mutant γCPs were crystallized as previously described for WT 20S proteasomes⁴⁶,⁴⁷. Crystals were grown at 20 °C using the hanging drop vapour diffusion method. Drops contained a 1:1 mixture of protein (40 mg ml⁻¹) and reservoir solution (25 mM magnesium acetate, 100 mM MES, pH 6.8, 30% (v/v) 2-methyl-2,4-pentanediol (MPD)). Crystals were cryoprotected by addition of 5 μl cryobuffer (20 mM magnesium acetate, 100 mM MES, pH 6.8, and 30% (v/v) MPD). Inhibitor complex structures were obtained by incubating crystals in 5 μl cryobuffer supplemented with bortezomib or carfilzomib at a final concentration of 1.5 mM for at least 8 h.

Diffraction data were collected at the beamline X06SA at the Paul Scherrer Institute, SLS, Villigen, Switzerland (λ = 1.0 Å). Evaluation of reflection intensities and data reduction were performed with the programme package XDS⁴⁸. Molecular replacement was carried out with the coordinates of the yeast 20S proteasome (PDB entry code: 5CZA) by rigid body refinements (REFMAC5; ref. 39). MAIN⁴⁰ and COOT⁴¹ were used to build models. TLS (Translation/Libration/Screw) refinements finally yielded excellent Rwork and Rfree, as well as root mean squared deviation bond and angle values. The coordinates, proven to have good stereochemistry from the Ramachandran plots, were deposited in the RCSB Protein Data Bank [Supplementary Table 1].

The coordinates for the yeast 20S proteasome deposited under the entry code 1RYP do not represent the WT γCP but the double-mutant β5-K33R β1-T1A. At the time of deposition (in 1997), these data were the best available on the γCP. As γCP structure determination has become routine today, and structure refinement procedures have significantly improved, here we provide coordinates for the WT γCP at 2.3 Å resolution (PDB entry code: 5CZA). Furthermore, the structures of most mutant γCPs described in this work were determined in their apo and ligand-bound states. For mutants with proteolytically inactive β5 subunits, the best crystallographic data obtained are given. For ligands or propeptide segments that were only partially defined in the 2Fᵢ–Fᵢ signal electron-density map the occupancy was reduced (for details see Supplementary Table 1).

References

1. Chen, P. & Hochstrasser, M. Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly. Cell 86, 961–972 (1996).
2. Groll, M. et al. Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature 386, 463–471 (1997).
3. Krüger, E., Köpkel, P. M. & Enenkel, C. 20S proteasome biogenesis. Biochimie 83, 289–293 (2001).
4. Groll, M. et al. The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study. Proc. Natl Acad. Sci. USA 96, 10976–10983 (1999).

NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10900 | www.nature.com/naturecommunications
5. Ditzel, L. et al. Conformational constraints for protein self-cleavage in the proteasome. J. Mol. Biol. 279, 1187–1191 (1998).
6. Arendt, C. S. et al. Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 148, 727–738 (2012).
7. Huber, E. M. et al. Systematic analyses of substrate preferences of 20S proteasomes using peptidic epoxyketoine inhibitors. J. Am. Chem. Soc. 137, 7835–7842 (2015).
8. Marques, A. J., Pash Exchange, R., Matias, A. C., Ramos, P. C. & Dohmen, R. J. Catalytic mechanism and assembly of the proteasome. Chem. Rev. 109, 1509–1536 (2009).
9. Löwe, J. et al. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 Å resolution. Science 268, 533–539 (1995).
10. Brannigan, J. A. et al. A protein catalytic framework with an N-terminal nucleophile is capable of self-activation. Nature 378, 416–419 (1995).
11. Seemüller, E. et al. Proteasome from Thermoplasma acidophilum: a threonine protease. Science 268, 579–582 (1995).
12. Dick, T. P. et al. Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants. J. Biol. Chem. 273, 25672–25676 (1998).
13. Heinemeyer, W., Fischer, M., Krimmer, T., Stachon, U. & Wolf, D. H. The proteasome beta-type subunits: unequal roles of propeptides in core particle maturation and a hierarchy of active site function. J. Mol. Biol. 291, 997–1013 (1999).
14. Arendt, C. S. & Hochstrasser, M. Eukaryotic 20S proteasome catalytic centers and subunit interactions required for active-site formation. Proc. Natl Acad. Sci. USA 94, 7156–7161 (1997).
15. Jäger, S., Groll, M., Huber, R., Wolf, D. H. & Heinemeyer, W. Proteasome beta-type subunits: unequal roles of propeptides in core particle maturation and a hierarchy of active site function. J. Mol. Biol. 291, 997–1013 (1999).
16. Arendt, C. S. & Hochstrasser, M. Eukaryotic 20S proteasome catalytic subunit precursors prevent active site inactivation by N-terminal acetylation and proteolytic particle assembly. EMBO J. 18, 3573–3585 (1999).
17. Polgar, L. The catalytic triad of serine proteasides. Cell. Mol. Life Sci. 62, 2161–2172 (2005).
18. Li, X., Li, Y., Arendt, C. S. & Hochstrasser, M. Distinct elements in the proteasomal beta subunit propeptide required for autocatalytic processing and proteasome assembly. J. Biol. Chem. 271, 19991–19993 (2006).
19. Schmidlke, G. et al. Analysis of mammalian 20S proteasome biogenesis: the maturation of beta-subunits is an ordered two-step mechanism involving autocatalysis. EMBO J. 15, 6887–6898 (1996).
20. Wlodawer, A. Proteasome: a complex protease with a new fold and a distinct mechanism. Structure 3, 417–420 (1995).
21. Seebüll, E., Lupas, A. & Baumeister, W. Autocatalytic processing of the 20S proteasome. Nature 382, 468–471 (1996).
22. Groll, M., Berkers, C. R., Ploegh, H. L. & Ovaa, H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 14, 451–456 (2006).
23. Huber, E. M., Heinemeyer, W. & Groll, M. Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914. Structure 23, 407–417 (2015).
24. Bochtler, M., Ditzel, L., Groll, M. & Huber, R. Crystal structure of heat shock locus V (HslV) from Escherichia coli. Proc. Natl Acad. Sci. USA 94, 6070–6074 (1997).
25. Groll, M., Brandstetter, H., Bartunik, H., Bourenkov, G. & Huber, R. Investigations on the maturation and regulation of archaeabacterial proteasomes. J. Mol. Biol. 327, 75–83 (2003).
26. Lukowski, J., Dauter, M., Aghaiypour, K., Wlodawer, A. & Dauter, Z. Atomic resolution structure of Ewinia chrysanthemi L-asparaginase. Acta Crystallogr. D Biol. Crystallogr. 59, 84–92 (2003).
27. Gutierrez, A. & Thornton, J. M. Understanding nature’s catalytic toolkit. Trends Biochem. Sci. 30, 622–629 (2005).
28. Hines, J., Groll, M., Fahnestock, M. & Crews, C. M. Proteasome inhibition by felbamate: B induces nerve growth factor synthesis. Chem. Biol. 15, 501–512 (2008).
29. Stein, M. L. et al. Systematic comparison of peptidic proteasome inhibitors highlights the alpha-ketoamide electrophile as an auspicious reversible lead motif. Angew. Chem. Int. Ed. 53, 1679–1683 (2014).
30. Groll, M., Laronov, O. V., Huber, R. & de Meijere, A. Inhibitor-binding mode of homobacillatoxin C to proteasomes: new insights into class I MHC ligand generation. Proc. Natl Acad. Sci. USA 103, 4576–4579 (2006).
31. Groll, M., Huber, R. & Potts, B. C. Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. J. Am. Chem. Soc. 128, 5136–5141 (2006).
32. Choi, K. S., Kim, J. A. & Kang, H. S. Effects of site-directed mutations on processing and activities of penicillin G acylase from Escherichia coli ATCC 11051. J. Bacteriol. 174, 6270–6276 (1992).
33. Khan, J. A., Dunn, B. M. & Tong, L. Crystal structure of human Taspase1, a crucial protease regulating the function of MLL. Structure 13, 1433–1452 (2005).
34. Kisselev, A. F., Songyang, Z. & Goldberg, A. L. Why does threonine, and not serine, function as the active site nucleophile in proteasomes? J. Biol. Chem. 275, 14831–14837 (2000).
35. Gallastegu, N. & Groll, M. Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies. Methods Mol. Biol. 832, 373–390 (2012).
36. Groll, M. & Huber, R. Purification, crystallization, and X-ray analysis of the yeast 20S proteasome. Methods Enzymol. 398, 329–336 (2005).
37. Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132 (2010).
38. Stein, M. L. et al. REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use. Acta Crystallogr. D Biol. Crystallogr. 60, 2184–2195 (2004).
39. Turk, D. MAIN software for density averaging, model building, structure refinement and validation. Acta Crystallogr. D Biol. Crystallogr. 69, 1342–1357 (2013).
40. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).

Acknowledgements
The staff of the beamline X06SA at the Paul Scherrer Institute, Swiss Light Source, Villigen, Switzerland is acknowledged for assistance during data collection. The research leading to these results has received funding from the European Community’s Seventh Framework Program (FP7/2007–2013) under BioStruct-X (grant agreement No. 283570). We are most grateful to Richard Feicht for the professional purification and crystalization of yeast proteasomes. This work was supported by the SFB 1035/A2 to M.H. as well as the U.S. National Institutes of Health grants GM046904 and GM083050 to M.H.

Author contributions
E.M.H., W.H., X.L., C.S.A. and M.H. created yeast mutants; E.M.H. and W.H. performed purification of yeast proteasomes. This work was supported by the SFB 1035/A2 to M.G. as well as the U.S. National Institutes of Health grants GM046904 and GM083050 to M.H.

Additional information
Accession codes: Coordinates and structure factors have been deposited in the Protein Data Bank, www.pdb.org (for PDB entry codes see Supplementary Table 1).

Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

How to cite this article: Huber, E. M. et al. A unified mechanism for proteolysis and autocatalytic activation in the 20S proteasome. Nat. Commun. 7:10900 doi: 10.1038/ncomms10900 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/